Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06284590 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
A Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by Philogen S.p.A..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 1
- Study location
NCT06284590 is a Phase 2 study of Melanoma Stage IV and Melanoma Stage III that is actively recruiting participants, run by Philogen S.p.A.. The registered enrollment target is 162 participants, above the 93-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (74% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06284590, a Phase 2 study of Melanoma Stage IV and Melanoma Stage III, is actively recruiting participants, sponsored by Philogen S.p.A..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.
Conditions Studied
Interventions
- DRUG L19TNF
- DRUG L19IL2
- DRUG L19IL2/L19TNF
- DRUG KEYTRUDA®
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06284590
The ClinicalTrials.gov registry entry for NCT06284590 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 93-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (74% higher). The listed sponsor is Philogen S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 4 interventions - of which L19TNF is the first listed.
NCT06284590 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06284590 about?
NCT06284590 is a clinical study titled "Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients". The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.
What is the current status of trial NCT06284590?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2024-07-12. Estimated completion is 2028-07.
What conditions does trial NCT06284590 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT06284590?
The interventions under investigation include: L19TNF (DRUG), L19IL2 (DRUG), L19IL2/L19TNF (DRUG), KEYTRUDA® (DRUG).
Who is sponsoring clinical trial NCT06284590?
This trial is sponsored by Philogen S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06284590 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
RECRUITING · Phase 2
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.